Research and Markets: Study the Zentiva Generics Company Intelligence Report Today

Business Wire, June 15, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c28710) has announced the addition of "Zentiva Generics Company Intelligence Report" to their offering.

The generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Zentiva was created through the merger of the Czech company, Leciva, and the Slovak firm Slovakofarma, which was completed in August 2003. The two former companies began selling products under the Zentiva name from the beginning of September 2003.

Zentiva specialises in the development of generics, and holds leading market positions in both the Czech and Slovak Republics. Outside of these two home markets, Zentiva's most important markets are those of Central and Eastern Europe, and in particular Poland and Russia. The company is establishing new businesses in other territories, including Lithuania, Latvia, Bulgaria and Ukraine.

Zentiva's top-selling brand is Helicid (omeprazole), which raised sales worth CZK767.8 million (US$32.3 million) in 2005. Other top sellers include Simvacard (simvastatin), with sales worth CZK707.5 million (US$29.7 million); Agapurin (pentoxyphylline), with sales worth CZK395.7 million (US$16.6 million) and Ibalgin (ibuprofen), with sales worth CZK381.8 million (US$16.1 million).

In April 2005, Zentiva launched its atorvastatin product in the Czech Republic, leading to a litigation battle with Pfizer.

In September 2005, Zentiva announced it had signed an agreement for the acquisition of 51% of the Romanian generics company, SC Sicomed SA. Zentiva added it intended to launch a Voluntary Tender Offer for the remaining 49% of the company.

In March 2006, sanofi-aventis acquired a 24.9% stake in Zentiva. The shares were purchased for 430.3 million euros, and have made sanofi-aventis Zentiva's largest shareholder.

Contents Include:

* Executive Summary

* Introduction

* Products

* Financial Results

* Major Developments

* Contact Details

Companies mentioned:

* sanofi-aventis

* Sicomed

* Litigation

* Atorvastatin

For more information visit http://www.researchandmarkets.com/reports/c28710.>

COPYRIGHT 2007 Business Wire

COPYRIGHT 2008 Gale, Cengage Learning